Navigation Links
Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
Date:5/23/2008

SAN DIEGO, May 23 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) today announced that its annual meeting of stockholders will be held on June 5, 2008 at 9:00 a.m. Pacific Time, at the San Diego Marriott Del Mar, 11966 El Camino Real, San Diego, California. The record date for stockholders entitled to vote at the annual meeting is April 10, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of patient temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more informatio
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
(Date:5/21/2015)... Calif. , May 21, 2015  The ... Orrin Hatch (R-UT) and Amy Klobuchar ... Extensions Now Accelerating Cures & Treatments, or OPEN ... rare disease patient advocacy organizations, this bipartisan legislation ... and affordable medicines to rare disease patients by ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... May 21, 2015 Veolia’s environmental ... exclusive North American distribution agreement with VWR to ... , With more than 160 years of experience, ... services for laboratory and production facilities, has cultivated ... and differentiated services to enable science. Endetec’s ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... At the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: ... remote magnetic ablation that it believes will enhance ... Navigation,System. In booth #917, Stereotaxis will exhibit ... Cardiodrive(R) System for enhanced remote,catheter control and improved ...
... 14 In meetings held in association,with the JP ... (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and ... approvals in 2009 in,addition to potential label expansion for ... Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... At the end of December,Trinitas Comprehensive Cancer Center ... state of New Jersey to offer cancer patients treatment ... VAR ).,RapidArc is a fast, precise form of ... is possible with conventional radiation therapy,technologies. By delivering ...
Cached Biology Technology:Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 2Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 3
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Presbycusis, or age-related hearing loss, accounts for 30 percent ... lose their hearing as they get older but other people ... answer may be in a study released online in the ... online at http://hmg.oxfordjournals.org/papbyrecent.dtl . "This ...
... find their way back to their birthplace to reproduce after ... scientists for more than a century. But marine biologists at ... might finally have unraveled the secret. At the beginning ... magnetic field of their home area and "imprint" on it, ...
... meaning of a rare mineral that can be used to track ... others better understand what we,re probably in for over the next ... heat and, ultimately, to change life as we know it. ... in the next hundred years or so, and that many species ...
Cached Biology News:House Ear Institute, TGen and Belgian researchers identify gene in age-related hearing loss 2No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3Foretelling a major meltdown 2Foretelling a major meltdown 3
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Biology Products: